Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascentage Reports Positive Trial Data for Two Apoptosis Candidates

publication date: Jun 6, 2019

Ascentage Pharma of Shanghai announced new clinical trial data from two apoptosis-targeted drug candidates, APG-115 (a novel MDM2-p53 inhibitor) and APG-1387 (a novel IAP inhibitor). In a small trial, APG-115 produced a confirmed partial response in one patient with liposarcoma, a soft-tissue sarcoma for which there is no approved treatment. The other candidate, APG-1387, produced stable disease in three of ten patients with metastatic pancreatic cancer, which generally has a survival time of three to six months. Ascentage is developing a portfolio of apoptosis drugs for cancer and other diseases. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital